Features of anesthetic management and anesthetic risks in patients taking combined oral contraceptives and menopausal hormone therapy
Authors:
- Daria YavorovskayaDYDaria Yavorovskaya
- Elena Alekseevna SosnovaESElena Alekseevna Sosnova
- Zhanna Eduardovna KharchevaZKZhanna Eduardovna Kharcheva
- Ludmila Alexandrovna KuznetsovaLKLudmila Alexandrovna Kuznetsova
- Andrei Vladimirovich MurashkoAMAndrei Vladimirovich Murashko
- Мурашко Андрей ВладимировичМВМурашко Андрей Владимирович
- Evgeniya Alexandra SvidinskayaESEvgeniya Alexandra Svidinskaya
Open Access
- 14 November 2026
- journal article
- Published by ECO-Vector LLC (Publications) in V.F.Snegirev Archives of Obstetrics and Gynecology
- Vol. 13 (3) , 222-228
Abstract
This review is based on the analysis of domestic and foreign studies published in peer-reviewed medical journals, and clinical guidelines devoted to anesthetic management of patients receiving combined oral contraceptives and menopausal hormone therapy. For the search of publications, the PubMed database and specialized Russian journals were used. The review included studies published in 1990–2025, with emphasis on systematic reviews, randomized controlled trials, large cohort studies, and current clinical guidelines. Combined oral contraceptives and menopausal hormone therapy are widely used in gynecology; however, they increase the risk of venous thromboembolic complications, especially in the perioperative period. Anesthetic management requires careful assessment of thrombotic risk, consideration of interactions of hormonal drugs with anesthetics, sugammadex, and antibiotics, as well as an individualized approach to continuation or discontinuation of therapy. It is recommended to discontinue oral forms of combined oral contraceptives and menopausal hormone therapy 4–6 weeks before high-risk operations, to give preference to transdermal forms of menopausal hormone therapy, to conduct enhanced thromboprophylaxis with low-molecular-weight heparins, and to mandatory inform patients about the need for additional contraception after the use of sugammadex. Particular attention should be given to patients with thrombophilias and comorbidity. Systematization of data contributes to improving the safety of anesthetic management in this category of patients.Keywords
This publication has 11 references indexed in Scilit:
- Russian eligibility criteria for prescription of menopausal hormone therapy to patients with cardiovascular and metabolic diseases. Agreement document of RKO, ROAG, RAE, EAT, AFR, RNMOT, RAGGProblems of Endocrinology, 2026
- Anesthesia Providers’ Knowledge of Medication Interference with Hormonal Contraception: A Multisite SurveyAnesthesia & Analgesia, 2024
- Efficacy and safety of personalized menopausal hormone therapy: a review of international guidelinesAkusherstvo i ginekologiia, 2024
- Withholding of Hormone Replacement Therapy Prior to Total Joint Arthroplasty Surgery to Reduce the Risk of Postoperative Thromboembolic Events: Is It Justified?—A Systematic Review of Clinical Practice GuidelinesThe Journal of Arthroplasty, 2023
- Perioperative Management of Estrogen Therapy As It Relates to Venous Thromboembolism in Aesthetic Surgery PatientsAesthetic Surgery Journal Open Forum, 2023
- Should Combined Hormonal Contraception Be Stopped in the Perioperative Period?NEJM Evidence, 2022
- Prevention of Venous Thromboembolism in Gynecologic SurgeryObstetrics & Gynecology, 2021
- Preoperative Management of Endocrine, Hormonal, and Urologic Medications: Society for Perioperative Assessment and Quality Improvement (SPAQI) Consensus StatementMayo Clinic Proceedings, 2021
- Drug Interactions Between Oral Contraceptives and AntibioticsObstetrics & Gynecology, 2001
- Hormone replacement therapy (HRT) and anaesthesiaBritish Journal of Anaesthesia, 2001